Psilocybin and obsessive compulsive disorder

Introduction

Obsessive Compulsive Disorder (OCD) is described as a chronic condition marked by intrusive, ego-dystonic thoughts and repetitive rituals, with a lifetime prevalence of about 2.5%, and substantial comorbidity with anxiety, insomnia and depression. The paper situates OCD as a severe public‑health problem with substantial morbidity and mortality and notes that, despite existing treatments, full symptomatic remission is uncommon; in some jurisdictions severe, invasive measures such as psychosurgery are still used. Previous clinical research and pharmacology implicate serotonin (5‑HT) in obsessive ideation and compulsive behaviour, and serotonergic agents can reduce symptoms in some patients, but robust, systematic research on serotonergic hallucinogens for OCD is very limited. This article presents a single clinical case in which an individual reported sustained reduction of core OCD symptoms after using psilocybin, a naturally derived serotonergic hallucinogen that acts as an agonist at 5‑HT1a, 5‑HT2a and 5‑HT2c receptors. The report is framed as illustrative rather than endorsing self‑medication: Wilcox highlights the gap between widespread clinical need and the paucity of controlled trials of psilocybin for OCD, arguing that such case reports can inform and motivate legitimate clinical research into this potential treatment avenue.